secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2026-10-22T20:30:15+00:00
Accession:  0001493152-26-048112
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 4.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Shuttle Pharmaceuticals dismisses Forvis Mazars as auditor; no successor engaged
--------------------------------------------------------------------------------

- Audit Committee and Board approved dismissal on Oct. 16, 2026, effective after the Q3 2026 Form 10-Q for the quarter ended Sept. 30, 2026.
- Forvis Mazars' FY2025 and FY2024 reports had no adverse opinion or disclaimer and were not qualified, but included a going-concern explanatory paragraph.
- No disagreements; reportable events limited to material weaknesses in accounting policies/close oversight, review and segregation of duties over journal entries/spreadsheets.
- Other weaknesses: ITGC super-user access and segregation-of-duties issues; entity-level controls over timely communication of material contracts; insufficient technical accounting/valuation expertise.
- As of the Oct. 22, 2026 filing, no replacement independent auditor had been engaged; Audit Committee authorized Forvis to respond to successor inquiries.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315226048112/0001493152-26-048112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315226048112/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-048112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer